Background: Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients.
Methods: To determine whether calcium acetate or sevelamer hydrochloride best achieves recently recommended treatment goals of phosphorus =5.5 mg/dL and Ca x P product =55 mg(2)/dL(2), we conducted an 8-week randomized, double-blind study in 100 hemodialysis patients.